MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer

被引：0
|
作者：
Rastogi, Priya
Toi, Masakazu
Harbeck, Nadia
Bourayou, Nawel
Frenzel, Martin
Johnston, Stephen
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[3] Univ Munich LMU, Breast Ctr, Munich, Germany
[4] Eli Lilly & Co, Paris, France
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-05-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [2] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, Erica
    DeMichele, Angela
    Gnant, Michael
    Barry, William
    Pfeiler, Georg
    Metzger, Otto
    Burstein, Harold
    Miller, Kathy
    Rastogi, Priya
    Loibl, Sibylle
    Goulioti, Theodora
    Zardavas, Dimitrios
    Fesl, Christian
    Koehler, Maria
    Huang-Bartlett, Cynthia
    Huang, Xin
    Piccart, Martine
    Winer, Eric
    Wolff, Antonio
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
    Gluz, Oleg
    Degenhardt, Tom
    Marschner, Norbert
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald
    Schinkoethe, Timo
    Graeser, Monika
    Wurstlein, Rachel
    Kuemmel, Sherko
    Harbeck, Nadia
    CANCER RESEARCH, 2021, 81 (04)
  • [4] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
    Gluz, Oleg
    Scheffen, Iris
    Degenhardt, Tom
    Marschner, Norbert Walter
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald E.
    Schinkoethe, Timo
    Graeser, Monika Karla
    Wuerstlein, Rachel
    Kuemmel, Sherko
    Bauer, Lelia
    Schem, Christian
    Fehm, Tanja N.
    Neubauer, Hans
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
    Rugo, H.
    O'Shaughnessy, J.
    Song, C.
    Broom, R.
    Gumus, M.
    Yamashita, T.
    San Antonio, B.
    Shahir, A.
    Zimmermann, A.
    Zagouri, F.
    Reinisch, M.
    BREAST, 2021, 56 : S23 - S24
  • [6] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
    Tolaney, Sara M.
    Fallowfield, Lesley
    Kaufman, Peter A.
    Ciruelos, Eva M.
    Gainford, Mary Corona
    Lu, Yi
    Hurt, Karla
    Wasserstrom, Heather Ann
    Chen, Yanyun
    Goel, Shom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer
    Mayer, E. L.
    Demichele, A. M.
    Pfeiler, G.
    Barry, W.
    Metzger, O.
    Rastogi, P.
    Symmans, F.
    Burstein, H. J.
    Miller, K.
    Loibl, S.
    Schmatloch, S.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Huang, X.
    Piccart, M.
    Winer, E.
    Gnant, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Huober, J.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C.
    Wei, R. J.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S151 - S151
  • [9] Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C. -S.
    Wei, R.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    SWISS MEDICAL WEEKLY, 2022, 152 : 48S - 48S
  • [10] Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2-early breast cancer.
    Shao Zhimin
    Zhang, Qingyuan
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne Wing Yan
    Tseng, Ling-Ming
    Qian, Chenxi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345